• Genoa in the News

Chain Drug Review features Genoa Healthcare’s integrated pharmacy model and the positive impact of community pharmacies on opioid use disorder

May 12th, 2023

Millions of Americans are living with mental illness, substance use disorder, and other complex, chronic health conditions. Recently, Chain Drug Review featured Genoa, which provides personalized, compassionate care using its integrated, on-site model to meet the needs of these often-medically underserved communities and provide accessible care.

“With every pharmacy we open and every medication we fill, we’re committed to serving our communities with the best-quality pharmacy care possible,” said Todd Gustin, CEO of Genoa, in the article. “We’re making a difference in the lives of people experiencing very tough circumstances.”

The article also shared results of a first-of-its-kind study from researchers at Brown University, Rhode Island Hospital and the University of Rhode Island that Genoa participated in which found that pharmacists — not just physicians at clinics and doctor’s offices — can safely and effectively start patients with opioid use disorder on the lifesaving medication buprenorphine.

The study documents the experiences of 100 patients who started taking buprenorphine after visiting a specially trained pharmacist for their care. Once stabilized on the medication, 58 patients were randomly assigned to receive either continued care in the pharmacy or usual care in a clinic or physician’s office.

After one month, the patients in the pharmacy care group showed dramatically higher rates of retention: 25 patients (89%) continued to receive treatment in the pharmacy compared to five (17%) in the usual care group.

“The study results are encouraging, and they highlight the role pharmacists can play in achieving positive health outcomes,” Tasha Hennessy, COO of Genoa, was quoted in the article. “The patients in this population just want to get healthy, but unfortunately they often experience barriers to care that make it hard for them to do so.”

Read the full article in Chain Drug Review’s recent issue.

Recent Posts

  • Blog Post
Partnering with ACT teams to make an even bigger impact

Genoa Healthcare® pharmacist Julie R. has seen firsthand the impact that severe and persistent mental illness can have on a person. For one of her consumers living with schizophrenia, the...

  • Blog Post
  • Webinar
For consumers living with Tardive Dyskinesia, Genoa Healthcare’s Clinical Assistance Program offers personalized support

Tardive Dyskinesia – a neurological disorder linked to prolonged use of antipsychotic medications – impacts over 600,000 individuals each year. Did you know that 50% of consumers taking TD medication...

  • Blog Post
A foundation to build on: 3 ways an engaged pharmacy partner helps you deliver whole-person health

A recent survey found that nearly 60% of behavioral health, primary care and complex care providers reported that their organization currently offered or had plans to begin offering integrated care...

  • Clinical Insights
  • Webinar
Understanding Tardive Dyskinesia: What you need to know

Tardive Dyskinesia (TD) – a neurological disorder associated with prolonged use of antipsychotic medications – affects over 600,000 people annually. Wondering what this means for the people you serve? Genoa...